TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25151205

Group type: EXPERIMENTAL
Intervention: Ertapenem (1 g infusion)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Ceftriaxone (2 g) and Metronidazole (500 mg)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 499

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 499
Study: 22490901

Group type: EXPERIMENTAL
Intervention: HNIPPV plus tiotropium bromide and doxofylline tablets
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (tiotropium bromide, doxofylline tablets, and low-flow inhalation of oxygen)
Number of subjects: 44
Study: 20123769

Group type: EXPERIMENTAL
Intervention: WBT + HOT
Number of subjects: 56

Group type: COMPARATOR
Intervention: WBT
Number of subjects: 56
Study: 18589554

Group type: EXPERIMENTAL
Intervention: Daidzein dripping pills (50 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Daidzein tablets (50 mg)
Number of subjects: 20
Study: 16078335

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg patch
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 12375713

Group type: EXPERIMENTAL
Intervention: Albuterol (200 microg, 2 inhalations via MDI with spacer)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg, 2 inhalations via MDI or Diskus)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (MDI with spacer)
Number of subjects: 10
Study: 10355006

Group type: EXPERIMENTAL
Intervention: Sealing of first permanent molars on one side
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sealing of unsealed side after three months
Number of subjects: 74
Study: 8522784

Group type: EXPERIMENTAL
Intervention: Behavioral effects during work hours
Number of subjects: 100
Study: 1874224

Group type: EXPERIMENTAL
Intervention: Stepwise rising propofol infusion regime of 0.24, 0.6 and 1.5 mg kg‐1 h‐1 for 75 min (25 min at each infusion rate)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (as a control)
Number of subjects: 6
Study: 31808410

Group type: EXPERIMENTAL
Intervention: Sertraline 50mg
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20mg
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Paroxetine 20mg
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Citalopram 20mg
Number of subjects: 480
Study: 28463874

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens/bazedoxifene 0.45 mg/20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens/bazedoxifene 0.625 mg/20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24748629

Group type: EXPERIMENTAL
Intervention: blisibimod 200 mg once-weekly (QW)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: blisibimod
Number of subjects: 547

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 547
Study: 23378102

Group type: EXPERIMENTAL
Intervention: (18)F-fluorothymidine (FLT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: (18)F-fluorodeoxyglucose (FDG)
Number of subjects: 30
Study: 20237929

Group type: EXPERIMENTAL
Intervention: Spa therapy (daily locally applied mud‐packs and bicarbonate‐sulphate mineral bath water)
Number of subjects: 30
Study: 19661449

Group type: EXPERIMENTAL
Intervention: Aminophylline (adenosine receptor antagonist)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Phentolamine (alpha‐adrenoceptor antagonist)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combined phentolamine and aminophylline administration
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Exogenous adenosine
Number of subjects: 18
Study: 17872717

Group type: EXPERIMENTAL
Intervention: Decision rules only
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rapid antigen test only
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Decision rules and antigen test combined
Number of subjects: 40
Study: 15471841

Group type: EXPERIMENTAL
Intervention: AAPM/Sgouros method blood model approach to marrow dosimetry
Number of subjects: 22

Group type: COMPARATOR
Intervention: Participating institution calculation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Central laboratory value
Number of subjects: 22
Study: 11552199

Group type: EXPERIMENTAL
Intervention: Knee immobilized (KI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Knee and arm immobilized (KAI)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Arm immobilized (AI)
Number of subjects: 10
Study: 9926057

Group type: EXPERIMENTAL
Intervention: Intensive community mental health service
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard community mental health service
Number of subjects: 0
Study: 8072714

Group type: EXPERIMENTAL
Intervention: Ketorolac 120 mg via PCA pump (20 mg initial bolus, 2 mg demand bolus, 5 min lock‐out time, 4 mg/h continuous infusion, 48 mg maximum dose not including initial bolus)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ketorolac 30 mg IM every 6 hours
Number of subjects: 28
Study: 3401025

Group type: EXPERIMENTAL
Intervention: Low-fluence CO2 laser irradiation at fluences of 3.0, 3.7, or 4.4 J/cm2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-fluence CO2 laser irradiation at fluences of 3.7 or 4.4 J/cm2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-fluence CO2 laser irradiation
Number of subjects: 6
Study: 30792141

Group type: EXPERIMENTAL
Intervention: Beefsteak tomato (250 g, 2 hours before sleep for 8 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study: 31686648

Group type: EXPERIMENTAL
Intervention: Standard clinical examination with supplemental transoral ultrasound
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard clinical examination (control)
Number of subjects: 88
Study: 28464700

Group type: EXPERIMENTAL
Intervention: Instant Heart Rate (IHR)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Heart Fitness (HF)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Whats My Heart Rate (WMH)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cardiio Version (CAR)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Pulse oximetry
Number of subjects: 108
Study: 25209170

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 242
Study: 24059377

Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided subacromial injections
Number of subjects: 98
Study: 21444699

Group type: EXPERIMENTAL
Intervention: MP-376 (levofloxacin inhalation solution) 180 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MP-376 (levofloxacin inhalation solution) 240 mg once daily for 7 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MP-376 (levofloxacin inhalation solution) 240 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MP-376 (levofloxacin inhalation solution)
Number of subjects: 10
Study: 18193962

Group type: EXPERIMENTAL
Intervention: New glass ionomer adhesive with 10% polyacrylic acid conditioning
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: New glass ionomer adhesive with 37% phosphoric acid conditioning
Number of subjects: 60

Group type: COMPARATOR
Intervention: Composite adhesive with 37% phosphoric acid conditioning (control)
Number of subjects: 60
Study: 16861547

Group type: EXPERIMENTAL
Intervention: MDCT scanner
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Single-detector scanner
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Screening efficacy
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Screening recommendation
Number of subjects: 1000
Study: 14960118

Group type: EXPERIMENTAL
Intervention: Sonification of range information using a point laser range sensor
Number of subjects: 0
Study: 10785875

Group type: EXPERIMENTAL
Intervention: Rilmenidine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 100
Study: 8620638

Group type: EXPERIMENTAL
Intervention: Physical therapy program (Group 2) designed to strengthen upper and lower limbs and improve knee range of motion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cardiovascular conditioning program (Group 3) consisting of arm ergometry, cycle ergometry, aquatic exercises, and aerobic activity
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Group 1) with no preoperative physical therapy
Number of subjects: 30
Study: 1458033

Group type: EXPERIMENTAL
Intervention: Bromocriptine (1.25 mg bid)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 20
Study: 6393460

Group type: EXPERIMENTAL
Intervention: Standard dose oral contraceptive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose oral contraceptive
Number of subjects: 0
Study: 29325799

Group type: EXPERIMENTAL
Intervention: Coexistence of HCY ≥ 14.65 μmol/l and hs-CRP ≥ 1.90 mg/l
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Combination of HCY and hs-CRP
Number of subjects: 598
Study: 27687366

Group type: EXPERIMENTAL
Intervention: Local Anesthetic Infiltration (LAI)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Spinal Anesthesia (SPIN)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Total Intravenous Anesthesia (TIVA)
Number of subjects: 156
Study: 24618303

Group type: EXPERIMENTAL
Intervention: Montelukast tablets and fluticasone propionate nasal spray (n = 64)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo and fluticasone propionate
Number of subjects: 128
Study: 22788915

Group type: EXPERIMENTAL
Intervention: Defibrillation Testing (DT)
Number of subjects: 145

Group type: COMPARATOR
Intervention: No Defibrillation Testing (No DT)
Number of subjects: 145
Study: 19713953

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Water fountains installed and lessons to promote water consumption
Number of subjects: 2950

Group type: COMPARATOR
Intervention: Control Group (CG) - No intervention
Number of subjects: 2950

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Water consumption promotion
Number of subjects: 2950
Study: 18700451

Group type: EXPERIMENTAL
Intervention: Micropulse Diode Laser Trabeculoplasty (MDLT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Argon Laser Trabeculoplasty (ALT)
Number of subjects: 26
Study: 15960404

Group type: EXPERIMENTAL
Intervention: Pressure-Support Ventilation (PSV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Airway Pressure Release Ventilation (APRV)
Number of subjects: 20
Study: 12823079

Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 100 mg daily)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Imipramine (100 to 200 mg daily)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 207

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 207
Study: 11114683

Group type: EXPERIMENTAL
Intervention: Dietary intake of alpha-linolenic acid (ALA)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Dietary intake of linoleic acid (LA)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: LA/ALA ratio
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Lowest quintile of CE ALA
Number of subjects: 266
Study: 8644683

Group type: EXPERIMENTAL
Intervention: Sucrose polyester (SPE)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control fat
Number of subjects: 2
Study: 1996743

Group type: EXPERIMENTAL
Intervention: Chloroquine (weekly for four weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chloroquine and No drug (both groups)
Number of subjects: 50
Study: 6468470

Group type: EXPERIMENTAL
Intervention: 1 g aspirin
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1 g paracetamol
Number of subjects: 40
Study: 30824428

Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28289041

Group type: EXPERIMENTAL
Intervention: CANA/PHEN
Number of subjects: 335

Group type: COMPARATOR
Intervention: PBO
Number of subjects: 335
Study: 25556022

Group type: EXPERIMENTAL
Intervention: Weight-loss surgery (WLS)
Number of subjects: 242
Study: 23339731

Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 21333876

Group type: EXPERIMENTAL
Intervention: IntraLase femtosecond laser (Group A)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: VisuMax femtosecond laser (Group B)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Both groups (Group A and Group B)
Number of subjects: 87
Study: 19018783

Group type: EXPERIMENTAL
Intervention: Low-dose pioglitazone (7.5 mg/day; 21/28 days)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low-dose flutamide (62.5 mg/day; 21/28 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Metformin and oestro-progestagen (control treatment)
Number of subjects: 38
Study: 17055728

Group type: EXPERIMENTAL
Intervention: Fall anxiety manipulation (increased threat to postural control)
Number of subjects: 30
Study: 14643577

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 to 10 mg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Valsartan (80 to 160 mg)
Number of subjects: 58
Study: 11287711

Group type: EXPERIMENTAL
Intervention: Enoxaparin 1.0 mg/kg intravenously (without abciximab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced dose enoxaparin 0.75 mg/kg in combination with standard-dose abciximab intravenously during PCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of low-dose, weight-adjusted unfractionated heparin and abciximab
Number of subjects: 0
Study: 9505993

Group type: EXPERIMENTAL
Intervention: Intravenous administration of valspodar (200 mg as a 2-hour infusion)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral administration of valspodar (400 mg as microemulsion soft gelatin capsules)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of intravenous and oral administration of valspodar
Number of subjects: 24
Study: 7939618

Group type: EXPERIMENTAL
Intervention: Lead in air (PbA) in the casting and pasting area: 92.01 micrograms/m3
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lead in air (PbA) in the assembly line area: 85.73 micrograms/m3
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lead in air (PbA) in the battery charging and sales area: 36.31 micrograms/m3
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lead in air (PbA) in the administration area: 4.2 micrograms/m3
Number of subjects: 20
Study: 3304403

Group type: EXPERIMENTAL
Intervention: Women holding their full case notes
Number of subjects: 290

Group type: COMPARATOR
Intervention: Women holding their co‐operation card
Number of subjects: 290
Study: 31280343

Group type: EXPERIMENTAL
Intervention: Pre-meal whey protein (WP) intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-meal whey protein (WP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-meal casein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-meal gluten
Number of subjects: 0
Study: 29504666

Group type: EXPERIMENTAL
Intervention: FamTechCare telehealth intervention providing individualized dementia-care strategies based on caregiver video recordings.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly phone call feedback for control group caregivers.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost for FamTechCare intervention.
Number of subjects: 0
Study: 26819195

Group type: EXPERIMENTAL
Intervention: Mipomersen
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 25704314

Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy (LLLT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 23034644

Group type: EXPERIMENTAL
Intervention: Resistance training (R)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Combined training (R + E)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Endurance training (E)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 46
Study: 21569370

Group type: EXPERIMENTAL
Intervention: Recreational Stimulation for Elders as a Vehicle to resolve DSD (RESERVE-DSD)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 256
Study: 19236277

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 17622
Study: 16449396

Group type: EXPERIMENTAL
Intervention: Evidence-based collaborative depression treatment (pharmacotherapy, problem-solving treatment, or both)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Usual primary care (routine medical services)
Number of subjects: 329
Study: 12711467

Group type: EXPERIMENTAL
Intervention: CT-guided cutting needle biopsy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Abrams' pleural biopsy (standard care)
Number of subjects: 50
Study: 10718681

Group type: EXPERIMENTAL
Intervention: Controlled-release carbamazepine (CBZ-CR) 400 mg initially, then 400 mg BID for 1 month
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 300 mg/day for 3 months
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) 1800 mg/day for 3 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 16
Study: 9184262

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients (group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients (group D)
Number of subjects: 45
Study: 1549830

Group type: EXPERIMENTAL
Intervention: Liquid oxygen
Number of subjects: 15

Group type: COMPARATOR
Intervention: Gaseous oxygen
Number of subjects: 15
Study: 3944270

Group type: EXPERIMENTAL
Intervention: TxB2 infusion at 0.1 ng/kg X min
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: TxB2 infusion at 1.0 ng/kg X min
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: TxB2 infusion at 5.0 ng/kg X min
Number of subjects: 4

Group type: COMPARATOR
Intervention: Aspirin treatment at 325 mg/d
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (vehicle alone)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Overall rate of entry of endogenous TxB2 into circulation
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Rate of disappearance of immunoreactive TxB2
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Maximal estimate of plasma concentration of endogenous TxB2
Number of subjects: 4
Study: 30354330

Group type: EXPERIMENTAL
Intervention: GIST (Genotype Informed Statin Therapy)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: SLCO1B1 testing
Number of subjects: 159
Study: 26630992

Group type: EXPERIMENTAL
Intervention: TFMPP (60 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexamphetamine (20 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Benzylpiperazine (BZP) (200 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: BZP + TFMPP (100/30 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 100
Study: 25518117

Group type: EXPERIMENTAL
Intervention: Acupoint injection of Metoclopramide (5 mg + normal saline) into bilateral Zusanli (ST 36) and Weishu (BL 21)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group treated by injection of 10 mg of Metoclopramide into the deltoid muscle and gluteus maximus muscle
Number of subjects: 46
Study: 22445775

Group type: EXPERIMENTAL
Intervention: Savory diet
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sweet diet
Number of subjects: 39

Group type: COMPARATOR
Intervention: Savory diet and Sweet diet
Number of subjects: 39
Study: 20147618

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study: 18217142

Group type: EXPERIMENTAL
Intervention: Aggrenox
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aspirin 81 mg
Number of subjects: 30
Study: 16251213

Group type: EXPERIMENTAL
Intervention: Acute exposure to galantamine (single dose)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Prolonged exposure to galantamine (5 days)
Number of subjects: 46
Study: 14604244

Group type: EXPERIMENTAL
Intervention: Intermittent prebypass heparin dosing (100 IU/kg, three consecutive doses with a 4 min interval)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard single prebypass heparin dose (300 IU/kg)
Number of subjects: 20
Study: 10623914

Group type: EXPERIMENTAL
Intervention: Counseling Group 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Counseling Group 2
Number of subjects: 0
Study: 9186303

Group type: EXPERIMENTAL
Intervention: Mono diet (n = 12)
Number of subjects: 28

Group type: COMPARATOR
Intervention: NCEP diet (n = 18)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Baseline diet (rich in fat and saturated fatty acids)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: M1M1 genotype
Number of subjects: 28
Study: 1584620

Group type: EXPERIMENTAL
Intervention: Computer-assisted optic nerve head analysis system
Number of subjects: 15
Study: 3847391

Group type: EXPERIMENTAL
Intervention: New approach to preoperative teaching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard preoperative teaching)
Number of subjects: 0
Study: 31070388

Group type: EXPERIMENTAL
Intervention: HIV-prevention interactive video intervention
Number of subjects: 540
Study: 27704654

Group type: EXPERIMENTAL
Intervention: Active tDCS with saline-soaked sponges of different thicknesses
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham tDCS with saline-soaked sponges of different thicknesses
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Thin sponges
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Thick sponges
Number of subjects: 26
Study: 25725625

Group type: EXPERIMENTAL
Intervention: Ephedrine 1.5 mg kg(‐1) day(‐1) for 28 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Acute ephedrine (2.5 mg/kg) after 28 days of treatment
Number of subjects: 23
Study: 23551710

Group type: EXPERIMENTAL
Intervention: Trivalent influenza virus vaccine (TIV) in pregnant women
Number of subjects: 56

Group type: COMPARATOR
Intervention: Trivalent influenza virus vaccine (TIV) in non-pregnant women
Number of subjects: 56
Study: 21775166

Group type: EXPERIMENTAL
Intervention: Aggressive targets for LDL-C, non-HDL-C and SBP
Number of subjects: 499

Group type: COMPARATOR
Intervention: Standard targets for LDL-C, non-HDL-C and SBP
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Aggressive and Standard targets
Number of subjects: 499
Study: 19838086

Group type: EXPERIMENTAL
Intervention: Abacavir/Lamivudine (ABC/3TC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Tenofovir/Emtricitabine (TDF/FTC)
Number of subjects: 21